Drug Trial Radar · NCT07752550
Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jul 30, 2026
Primary completion
Jul 30, 2028
Study completion Jul 30, 2029
Sponsor
- Lead sponsor
- Harbin Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigate the efficacy and safety of Retlirafusp alfa in combination with chemotherapy or fluzoparib for early-stage and advanced triple-negative breast cancer.
Conditions
- Triple-Negative Breast Cancer (TNBC)
Interventions
Retlirafusp alfa+Nab-paclitaxel:Drug
Retlirafusp alfa+Nab-paclitaxel
Retlirafusp alfa+FluzoparibDrug
Retlirafusp alfa+Fluzoparib
Retlirafusp alfa+TP-ACDrug
Retlirafusp alfa+TP-AC
Retlirafusp alfa+FluzoparibDrug
Retlirafusp alfa+Fluzoparib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Late-Stage Cohort-Objective Response RateTime frame: Assessed every 6 weeks (every 2 cycles) during treatment until disease progression, death, or loss to follow-up. Analysis cutoff at 6 months.
- Neoadjuvant Cohort-tpCR (ypT0/is ypN0)Time frame: Surgery performed 2-6 weeks after completing 8 cycles (≈24 weeks) of neoadjuvant therapy; pathological assessment post-surgery. Analysis cutoff at 6 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.